BioMarin Pharmaceutical Signs an Agreement with Deep Genomics on Advancing Programs Identified Using Artificial Intelligence

Shots:

  • Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones, BioMarin will receive an exclusive option to obtain Deep Genomics’ rights to each program for development & commercialization
  • Deep Genomics will use its AI drug discovery platform (The AI workbench) to identify & validate target mechanisms, lead candidates & BioMarin will advance them into preclinical & clinical development
  • AI workbench enables rapid exploration of novel targetable mechanisms & therapeutic candidates, it combines deep learning, automation, advanced biomedical knowledge & massive amounts of in vitro & in vivo data to accurately identify targetable molecular mechanisms & guide the discovery & development of oligonucleotide therapies

Click here ­to­ read full press release/ article | Ref: BioMarin | Image: BioMarin

The post BioMarin Pharmaceutical Signs an Agreement with Deep Genomics on Advancing Programs Identified Using Artificial Intelligence first appeared on PharmaShots.

FDA rejects BioMarin’s hemophilia A gene therapy in ‘massive surprise’

In a CRL issued for valoctocogene roxaparvovec, the FDA told BioMarin that differences between its Phase I/II and Phase III studies limited the ability to rely on the earlier trial to support durability of effect, which an analyst said likely referred to a product comparability issue.